June 15 (Reuters) - Celgene Corp:
* Announces positive top line data from randomized controlled phase II study of
apremilast in psoriatic arthritis
* Says efficacy and adverse event profile supports starting pivotal phase III
studies in the first half of 2010
* Says study met its primary objective of assessment of ACR20 at 12 weeks
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Announces positive top line data from randomized controlled phase II study of
apremilast in psoriatic arthritis
* Says efficacy and adverse event profile supports starting pivotal phase III
studies in the first half of 2010
* Says study met its primary objective of assessment of ACR20 at 12 weeks
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.